ReGelTec

Executive Summary

ReGelTec is a Baltimore-based clinical-stage medical device company developing HYDRAFIL, an injectable, thermosensitive hydrogel for minimally invasive treatment of chronic low back pain caused by degenerative disc disease. The hydrogel is designed to be percutaneously injected into the intervertebral disc, where it augments and repairs disc tissue, restoring function and alleviating pain while preserving spinal motion. Founded in 2015, the company is currently in Phase 1 clinical trials and represents a promising alternative to more invasive surgical interventions for a large patient population with limited treatment options.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 trial interim data readout60% success
• Q1 2027FDA Investigational Device Exemption (IDE) approval for pivotal study70% success
• Q4 2026Strategic partnership or licensing deal for commercialization40% success